Cytokinetics Inc
CYTK36.650USD
-0.040-0.11%
交易中 （美东）报价延迟15分钟
4.37B总市值
亏损市盈率 TTM
关于 Cytokinetics Inc 公司
Cytokinetics, Incorporated 是一家后期专业心血管生物制药公司，专注于发现、开发和商业化肌肉生物学导向的候选药物，作为治疗心肌功能受损的衰弱性疾病的潜在疗法。该公司致力于心脏肌球蛋白抑制剂 aficamten 的商业化，并正在对阻塞性和非阻塞性肥厚性心肌病患者进行额外的临床试验评估。该公司还在开发心脏肌球蛋白激活剂 omecamtiv mecarbil，用于治疗射血分数严重降低 (HFrEF) 的心力衰竭患者；CK-586，一种心脏肌球蛋白抑制剂，可用于治疗射血分数保留的心力衰竭 (HFpEF)；CK-089，一种快速骨骼肌肌钙蛋白激活剂，可用于治疗特定类型的肌营养不良症和其他骨骼肌功能受损的情况。
公司简介
公司代码CYTK
公司名称Cytokinetics Inc
上市日期Apr 29, 2004
CEOMr. Robert I. Blum
员工数量498
证券类型Ordinary Share
年结日Apr 29
公司地址350 Oyster Point Boulevard
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94080
电话16506243000
网址https://cytokinetics.com/
公司代码CYTK
上市日期Apr 29, 2004
CEOMr. Robert I. Blum
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Robert I. Blum
Mr. Robert I. Blum
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
229.51K
-6.13%
Dr. Fady Ibraham Malik, M.D., Ph.D.
Dr. Fady Ibraham Malik, M.D., Ph.D.
Executive Vice President - Research and Development
Executive Vice President - Research and Development
77.01K
--
Dr. John T. Henderson, M.D.
Dr. John T. Henderson, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
69.01K
+0.82%
Dr. Wendell Wierenga, Ph.D.
Dr. Wendell Wierenga, Ph.D.
Independent Director
Independent Director
26.83K
+0.62%
Ms. Nancy J. Wysenski
Ms. Nancy J. Wysenski
Independent Director
Independent Director
25.26K
+0.65%
Dr. Edward M. (Ed) Kaye, M.D.
Dr. Edward M. (Ed) Kaye, M.D.
Independent Director
Independent Director
24.56K
+1.35%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
17.91K
+48.87%
Mr. Robert E. (Bob) Landry
Mr. Robert E. (Bob) Landry
Independent Director
Independent Director
7.33K
--
Ms. Diane Weiser
Ms. Diane Weiser
Investors Relations
Investors Relations
--
--
Dr. Robert A Harrington, M.D.
Dr. Robert A Harrington, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Robert I. Blum
Mr. Robert I. Blum
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
229.51K
-6.13%
Dr. Fady Ibraham Malik, M.D., Ph.D.
Dr. Fady Ibraham Malik, M.D., Ph.D.
Executive Vice President - Research and Development
Executive Vice President - Research and Development
77.01K
--
Dr. John T. Henderson, M.D.
Dr. John T. Henderson, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
69.01K
+0.82%
Dr. Wendell Wierenga, Ph.D.
Dr. Wendell Wierenga, Ph.D.
Independent Director
Independent Director
26.83K
+0.62%
Ms. Nancy J. Wysenski
Ms. Nancy J. Wysenski
Independent Director
Independent Director
25.26K
+0.65%
Dr. Edward M. (Ed) Kaye, M.D.
Dr. Edward M. (Ed) Kaye, M.D.
Independent Director
Independent Director
24.56K
+1.35%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
11.69%
T. Rowe Price Investment Management, Inc.
11.24%
The Vanguard Group, Inc.
9.90%
Wellington Management Company, LLP
6.69%
Fidelity Management & Research Company LLC
6.38%
Other
54.11%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
11.69%
T. Rowe Price Investment Management, Inc.
11.24%
The Vanguard Group, Inc.
9.90%
Wellington Management Company, LLP
6.69%
Fidelity Management & Research Company LLC
6.38%
Other
54.11%
股东类型
持股股东
占比
Investment Advisor
59.12%
Investment Advisor/Hedge Fund
37.54%
Hedge Fund
13.26%
Research Firm
4.93%
Private Equity
2.08%
Pension Fund
1.79%
Sovereign Wealth Fund
0.83%
Bank and Trust
0.76%
Individual Investor
0.71%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
769
145.68M
121.98%
-6.27M
2025Q1
797
140.59M
117.75%
-12.63M
2024Q4
779
136.46M
115.26%
-16.24M
2024Q3
771
140.16M
119.20%
-8.76M
2024Q2
761
139.65M
120.41%
+11.58M
2024Q1
733
121.60M
116.11%
-3.04M
2023Q4
661
118.12M
120.45%
-1.38M
2023Q3
589
114.14M
118.93%
-7.33M
2023Q2
585
113.47M
118.68%
-8.63M
2023Q1
579
113.58M
118.87%
-6.12M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
13.96M
11.69%
-54.58K
-0.39%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
13.42M
11.24%
+3.46M
+34.80%
Apr 30, 2025
The Vanguard Group, Inc.
11.82M
9.9%
-67.91K
-0.57%
Mar 31, 2025
Wellington Management Company, LLP
7.99M
6.69%
+100.04K
+1.27%
Mar 31, 2025
Fidelity Management & Research Company LLC
7.62M
6.38%
-1.15M
-13.09%
Mar 31, 2025
State Street Global Advisors (US)
6.09M
5.1%
-82.34K
-1.34%
Mar 31, 2025
Deep Track Capital LP
3.07M
2.57%
+573.85K
+22.95%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.94M
2.46%
+96.15K
+3.38%
Mar 31, 2025
RTW Investments L.P.
2.72M
2.28%
--
--
Mar 31, 2025
Fidelity Institutional Asset Management
2.70M
2.26%
+668.11K
+32.88%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
ALPS Medical Breakthroughs ETF
2.67%
Tema Heart & Health ETF
1.51%
SPDR S&P Biotech ETF
1.42%
Virtus LifeSci Biotech Clinical Trials ETF
0.9%
Direxion Daily S&P Biotech Bull 3X Shares
0.81%
NYLI Healthy Hearts ETF
0.52%
T Rowe Price Capital Appreciation Equity ETF
0.51%
Invesco Nasdaq Biotechnology ETF
0.44%
ProShares Ultra Nasdaq Biotechnology
0.44%
Harbor Health Care ETF
0.42%
查看更多
ALPS Medical Breakthroughs ETF
占比2.67%
Tema Heart & Health ETF
占比1.51%
SPDR S&P Biotech ETF
占比1.42%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.9%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.81%
NYLI Healthy Hearts ETF
占比0.52%
T Rowe Price Capital Appreciation Equity ETF
占比0.51%
Invesco Nasdaq Biotechnology ETF
占比0.44%
ProShares Ultra Nasdaq Biotechnology
占比0.44%
Harbor Health Care ETF
占比0.42%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
